文献速递心脑血管急症重症综合管理与镇静镇痛

脑膜中动脉栓塞治疗慢性硬膜下血肿

Embolization of the Middle Meningeal Artery for Chronic Subdural Hematoma.
PubMed 文献 · N Engl J Med · 2024-11-20
一句话结论症状性慢性硬膜下血肿患者中,辅助脑膜中动脉栓塞较单纯标准治疗降低治疗失败风险(16% vs 36%,OR 0.36),短期未增加致残性卒中或死亡。

本研究将310例症状性慢性硬膜下血肿患者随机分为辅助脑膜中动脉栓塞组(149例)和单纯标准治疗组(161例),标准治疗可为手术或非手术。主要疗效终点为180天内复发或残留血肿(>10 mm)、再手术或手术挽救、重大致残性卒中、心肌梗死或神经原因死亡的复合终点。栓塞组主要终点事件发生率为16%(19/120),对照组为36%(47/129),OR 0.36(95%CI 0.20-0.66,P=0.001)。主要安全终点(30天内重大致残性卒中或全因死亡)两组均为3%。作者认为辅助栓塞降低治疗失败风险且短期未增加致残性卒中或死亡,需进一步研究长期安全性。

要点

  • 症状性慢性硬膜下血肿患者中,辅助脑膜中动脉栓塞组180天内主要疗效终点事件发生率为16%(19/120),对照组为36%(47/129),OR 0.36(95%CI 0.20-0.66,P=0.001)。
  • 主要安全终点(30天内重大致残性卒中或全因死亡):栓塞组3%(4/144),对照组3%(5/166)。
  • 180天内全因死亡:栓塞组8%(12例),对照组5%(9例);神经原因死亡:栓塞组1%(1例),对照组2%(3例)。
  • 研究纳入310例患者,平均年龄73岁,70%为男性;189例随机前已选择手术标准治疗,121例为非手术治疗。

适用人群与场景

  • 症状性慢性硬膜下血肿患者,随机前已确定接受手术或非手术标准治疗。
  • 共纳入310例,平均年龄73岁,70%为男性;栓塞组149例,对照组161例;手术标准治疗189例,非手术标准治疗121例。

诊断标准与关键阈值

  • 主要疗效终点为180天内复发或残留慢性硬膜下血肿(>10 mm)、再手术或手术挽救、重大致残性卒中、心肌梗死或神经原因死亡的复合终点。
  • 主要安全终点为30天内重大致残性卒中或全因死亡的复合终点。

研究设计与关键结果

  • 随机对照试验(STEM,NCT04410146),纳入310例症状性慢性硬膜下血肿患者,随机分为辅助脑膜中动脉栓塞组(149例)和单纯标准治疗组(161例)。
  • 主要疗效终点事件:栓塞组16%(19/120) vs 对照组36%(47/129),OR 0.36(95%CI 0.20-0.66,P=0.001)。
  • 主要安全终点事件(30天内重大致残性卒中或全因死亡):栓塞组3%(4/144) vs 对照组3%(5/166)。
  • 180天内全因死亡:栓塞组8%(12例) vs 对照组5%(9例);神经原因死亡:栓塞组1%(1例) vs 对照组2%(3例)。

证据类型、等级与局限

  • 研究类型:随机对照试验。
  • 局限:作者指出需进一步研究长期安全性结局。

对床旁实践的改变

  • 作者认为,在症状性慢性硬膜下血肿患者中,辅助脑膜中动脉栓塞较单纯标准治疗降低治疗失败风险,短期未增加致残性卒中或死亡发生率。
  • 作者指出需进一步研究长期安全性结局。

指南或共识出处

  • STEM试验(ClinicalTrials.gov NCT04410146),由Balt USA资助,发表于N Engl J Med。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Patients receiving standard treatment for chronic subdural hematoma have a high risk of treatment failure. The effect of adjunctive middle meningeal artery embolization on the risk of treatment failure in this population remains unknown.

METHODS: We randomly assigned patients with symptomatic chronic subdural hematoma to undergo middle meningeal artery embolization as an adjunct to standard treatment (embolization group) or to receive standard treatment alone (control group). Either surgical or nonsurgical standard treatment had been chosen for each patient before randomization. The primary efficacy outcome was a composite of the following events: recurrent or residual chronic subdural hematoma (measuring >10 mm) at 180 days; reoperation or surgical rescue within 180 days; or major disabling stroke, myocardial infarction, or death from neurologic causes within 180 days. The primary safety outcome was a composite of major disabling stroke or death from any cause within 30 days.

RESULTS: Among 310 enrolled patients, 149 were randomly assigned to the embolization group and 161 to the control group; 189 patients were to receive surgical standard treatment and 121 nonsurgical standard treatment. The mean age of the patients was 73 years, and 70% were men. In the primary efficacy analysis, a primary-outcome event occurred in 19 of 120 patients (16%) in the embolization group, as compared with 47 of 129 patients (36%) in the control group (odds ratio, 0.36; 95% confidence interval, 0.20 to 0.66; P = 0.001). In the primary safety analysis, 4 of 144 patients (3%) in the embolization group and 5 of 166 patients (3%) in the control group either had a major disabling stroke or died within 30 days. Through 180 days, 12 patients (8%) in the embolization group and 9 patients (5%) in the control group had died, with death from neurologic causes occurring in 1 patient (1%) in the embolization group and in 3 patients (2%) in the control group.

CONCLUSIONS: Among patients with symptomatic chronic subdural hematoma, adjunctive middle meningeal artery embolization resulted in a lower risk of treatment failure than standard treatment alone, without resulting in an increased incidence of disabling stroke or death in the short term. Further study of longer-term safety outcomes is warranted. (Funded by Balt USA; STEM ClinicalTrials.gov number, NCT04410146.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Fiorella D, Monteith SJ, Hanel R, et al. Embolization of the Middle Meningeal Artery for Chronic Subdural Hematoma. N Engl J Med. 2024. PMID: 39565980. doi:10.1056/NEJMoa2409845

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。